Search Results

You are looking at 1 - 10 of 86 items for :

  • pituitary adenoma x
Clear All
Open access

Tao Mei, Jianhe Zhang, Liangfeng Wei, Xingfeng Qi, Yiming Ma, Xianhua Liu, Shaohua Chen, Songyuan Li, Jianwu Wu and Shousen Wang

Introduction Pituitary adenomas (PA) are among the most common intracranial tumors, accounting for 10–15% of primary intracranial tumors ( 1 ). It has been confirmed by positron emission tomography and tumor cell culture experiments that PA

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

Introduction Clinically apparent pituitary adenomas are present in about 1:1000 of the general population in Europe; the most frequent sub-types are prolactinomas, non-secreting adenomas and somatotropinomas, while Cushing’s disease and

Open access

Paula Bruna Araujo, Leandro Kasuki, Carlos Henrique de Azeredo Lima, Liana Ogino, Aline H S Camacho, Leila Chimelli, Márta Korbonits and Monica R Gadelha

Introduction Although most pituitary adenomas occur sporadically, with only 5% of all cases being related to inherited syndromes ( 1 ), the mechanisms underlying pituitary tumorigenesis in a non-familial setting are poorly understood. Somatic

Open access

Ali Abbara, Sophie Clarke, Pei Chia Eng, James Milburn, Devavrata Joshi, Alexander N Comninos, Rozana Ramli, Amrish Mehta, Brynmor Jones, Florian Wernig, Ramesh Nair, Nigel Mendoza, Amir H Sam, Emma Hatfield, Karim Meeran, Waljit S Dhillo and Niamh M Martin

apoplexy may occur in either functioning or non-functioning pituitary tumours, but a higher predominance in non-functioning pituitary adenoma (NFPA) is recognised ( 2 , 4 , 5 , 6 , 10 ). Patients with pre-existing pituitary adenoma have a 2–12% chance

Open access

Morten Winkler Møller, Marianne Skovsager Andersen, Christian Bonde Pedersen, Bjarne Winther Kristensen and Frantz Rom Poulsen

Introduction Pituitary adenomas (PAs) account for 10–25% of intracranial tumors ( 1 , 2 , 3 ). They arise from adenohypophyseal cells, despite their benign nature, 25–55% of PAs show invasive growth ( 4 ), expanding into suprasellar ( 5

Open access

Nadine M Vaninetti, David B Clarke, Deborah A Zwicker, Churn-Ern Yip, Barna Tugwell, Steve Doucette, Chris Theriault, Khaled Aldahmani and Syed Ali Imran

the following inclusion criteria: i) seen between January 1, 2006, and June 30, 2014; ii) have any of the following diagnoses: non-functioning pituitary adenoma (NFA), prolactinoma (PRLoma), growth hormone-producing adenoma (GH adenoma

Open access

Kunal Thakkar, Swati Ramteke-Jadhav, Rajeev Kasaliwal, Saba Samad Memon, Virendra Patil, Puja Thadani, Nilesh Lomte, Shilpa Sankhe, Atul Goel, Sridhar Epari, Naina Goel, Anurag Lila, Nalini S Shah and Tushar Bandgar

non-neoplastic etiologies can be found in this region ( 1 ). Pituitary adenomas are the commonest SSR tumors accounting for 85% of sellar masses ( 2 ). Amidst the non-adenoma masses, other common sellar lesions include craniopharyngioma (CR, 12

Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp and Gunter Karl Stalla

non-functioning pituitary adenomas (NFPA) without history of dopaminergic treatment. The total prevalence of ICDs was significantly higher in patients with prolactinomas (24.6%-referring to the prevalence of one or more ICD) compared to the NFPA group

Open access

Anastasia P Athanasoulia-Kaspar, Matthias K Auer, Günter K Stalla and Mira Jakovcevski

, pituitary tumors such as somatotropic and corticotropic adenomas resulting in hormone excess conditions such as acromegaly ( 12 , 13 ) and Cushing’s syndrome ( 13 ) have been associated with accelerated telomere shortening ( 14 , 15 ), suggesting that TL

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

syndromes such as multiple endocrine neoplasia type 1 (MEN1), McCune–Albright Syndrome (MAS), Carney complex, and the emerging pheochromocytoma-paraganglioma-pituitary adenoma association (3PA) ( 7 ). Mutations in the aryl hydrocarbon receptor interacting